Effect of Mupirocin in patients with refractory chronic rhinosinusitis - A prospective, randomised double-blinded controlled trial

Effect of Mupirocin on S.aureus infection in patients with refractory chronic rhinosinusitis - A prospective, randomised double-blinded controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000994987

Enrollment

Registered

2011-09-19

Start date

2010-01-18

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We hypothesise that Mupirocin nasal rinses are more efficacious compared to placebo in patients that are bothered by persistent S.aureus infection despite complete sinus surgery.

Interventions

Mupirocin nasal rinses, 0.05% twice daily for 4 weeks.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with surgically-recalcitrant, S.aureus-positive chronic rhinosinusitis

Exclusion criteria

Mupirocin allergy. Augmentin Duo allergy. Multiple bacterial species on culture. MRSA. Mupirocin-resistant S.aureus.

Outcome results